Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.78 -	3.06 291.59%	3.17 3.63%	2.68 15.60%	2.87 7.34%	7.12 147.89%
company equity multiplier	-0.29 -	1.15 493.30%	-6.45 660.30%	-2.64 59.04%	-1.08 58.97%	1.11 201.97%
days of inventory outstanding
days of payables outstanding						653.80 -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.06 -	0.97 8.37%	2.04 109.21%	1.00 50.91%	0.97 2.82%	0.86 11.73%
effective tax rate		-0.03 -	0.00 105.87%	0.00 45.60%	-0.00 362.76%
enterprise value multiple	-49.33 -	-23.97 51.40%	-376.87 1,472.05%	-10.55 97.20%	-9.20 12.81%	-4.71 48.79%
fixed asset turnover
free cash flow per share	-0.93 -	-2.33 150.85%	-0.22 90.62%	-0.47 114.96%	-1.24 164.47%	-1.73 38.95%
gross profit margin
interest coverage					31.87 -
inventory turnover
long term debt to capitalization
net income per ebt	1 -	1 0%	1.00 0.16%	1.00 0.07%	1.00 0.32%	1 0.23%
net profit margin
operating cash flow per share	-0.93 -	-2.32 149.25%	-0.21 91.04%	-0.47 124.34%	-1.22 162.11%	-1.72 41.25%
operating profit margin
payables turnover						0.56 -
pretax profit margin
price fair value	-21.53 -	19.60 191.01%	-178.54 1,011.10%	-8.62 95.17%	-5.60 35.10%	2.00 135.74%
receivables turnover
return on assets	-1.47 -	-0.70 52.11%	-0.14 79.49%	-0.22 50.90%	-0.45 107.78%	-0.26 41.90%
return on capital employed	-1.82 -	-0.83 54.41%	-0.07 91.32%	-0.23 219.96%	-0.53 129.03%	-0.34 35.58%
return on equity	0.43 -	-0.81 288.35%	0.93 214.93%	0.58 38.20%	0.49 14.74%	-0.29 159.24%
total debt to capitalization			-0.01 -	-0.00 28.41%	-0.00 13.46%	0.00 132.22%

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.41

22/11 21:00

Market Cap

1.08B

Beta: -

Volume Today

254.16K

Avg: -

Preview